New Jersey sits at the center of the United States pharmaceutical industry. The Route 1 corridor between Princeton and New Brunswick — sometimes called “Pharma Alley” — hosts Pfizer, Johnson & Johnson, Bristol Myers Squibb, and dozens of smaller manufacturers and contract packagers. For every one of these companies, the Drug Supply Chain Security Act (DSCSA) determines what must appear on pharmaceutical product labels.
As of November 27, 2024, DSCSA’s full electronic traceability requirements are in effect. Every prescription drug package must carry a serialized product identifier — a GS1-compliant DataMatrix barcode encoding four specific data elements — and manufacturers, repackagers, wholesale distributors, and dispensers must be capable of exchanging and verifying electronic transaction information at the unit level.
Here’s what NJ pharmaceutical manufacturers need to understand about DSCSA label requirements.
FDA requires that each saleable unit (the smallest package sold to a dispenser) carry a product identifier containing four elements encoded in a GS1 DataMatrix barcode and also represented in human-readable form:
These four elements must appear on the label of every package — from the smallest unit (e.g., a single blister card) up through intermediate packaging and homogeneous cases.
Earlier generations of pharmaceutical labeling used linear barcodes (Code 128 or Code 39) for NDC and lot information. DSCSA mandates GS1 DataMatrix — a two-dimensional matrix barcode — for serialized product identifiers because:
Density: A GS1 DataMatrix can encode all four required data elements (GTIN, serial, lot, expiration) plus Application Identifier delimiters in a symbol small enough for unit-dose packaging.
Error correction: DataMatrix includes built-in error correction that allows the symbol to be read even if partially obscured or damaged — critical in pharmaceutical environments where label smudging or edge wear is common.
GS1 standardization: Using GS1 syntax (Application Identifiers, GTINs derived from registered NDC numbers) ensures the symbol is readable by any GS1-compliant scanner in the supply chain, from your facility to the dispensing pharmacy.
FDA’s guidance and GS1 standards specify that a GS1 DataMatrix symbol must be at least 5mm × 5mm — roughly 0.2” × 0.2”. For unit-dose packaging (oral solid blisters, unit-dose syringes, prefilled pens), this is a significant design constraint.
On small package surfaces where the 5mm minimum cannot be met while maintaining other required labeling elements, FDA allows for a reduced-size symbol with demonstrated scan reliability.
GS1 requires DataMatrix symbols to meet ISO/IEC 15415 verification grades. Grade 1.5 or higher (on a scale of 0 to 4) is typically required for pharmaceutical applications.
Print quality failures in pharmaceutical serialization are expensive: a batch of labels that fails to scan in a dispenser’s verification system can trigger a return, trigger FDA notification requirements, or — in serious cases — require package relabeling under controlled conditions.
At Certified Labeling Solutions, we verify DataMatrix print quality on all pharmaceutical label orders and provide ISO grade documentation for manufacturer validation records.
In addition to the machine-readable DataMatrix symbol, FDA requires human-readable text representing all four data elements adjacent to the barcode. This allows manual verification and supports pharmacist cross-checking during dispensing.
One of the most operationally significant DSCSA requirements now in full effect is the obligation to verify saleable returns before redistribution. When a wholesale distributor receives a returned prescription drug, they must verify the product identifier on the returned package — either by scanning the DataMatrix or through a system-to-system verification request — before returning it to saleable stock.
This requirement means the DataMatrix on your labels must be scannable across the entire product shelf life, including after the package has been opened, handled, and returned. Label materials that degrade, labels that fall off, or symbols that smudge on the package surface create supply chain disruption for your distributor customers.
Material recommendations for DSCSA-compliant labels:
Serialization requires that every label carry a unique serial number within each NDC. This means the serial number — and often the lot and expiration date — must be printed as variable data, changing with every label.
The two primary approaches:
Inline variable data printing: A digital or thermal transfer print engine integrated into the label production line applies the serialized fields to a pre-printed label substrate at packaging time. The pre-printed elements (brand, NDC, inactive ingredients, warnings) are produced on our flexographic presses; the variable fields are printed inline at your facility.
Pre-serialized labels: For manufacturers without inline printing capability, we can pre-serialize labels — printing unique serial numbers on every label in a roll or sheet — with sequential or algorithmically generated serial numbers. Your serialization system tracks which serial number range is in which label shipment.
Either approach requires a serialization management system capable of generating unique serial numbers, maintaining records for 6 years post-transaction, and responding to FDA verification requests.
New Jersey pharmaceutical manufacturers have specific supply chain characteristics that influence label design:
Cold chain products: Biologics, insulin, and other cold-chain products require labels that maintain DataMatrix readability through temperature cycling. We test label adhesion and print quality through 2°C–8°C refrigeration cycles and at -20°C for frozen biologics.
Contract packaging: Many NJ pharma companies use contract packagers (CMOs) for final labeling and packaging. If you’re a CMO producing labels for multiple manufacturers, your serialization system must be capable of managing multiple NDC/GTIN pools and maintaining chain of custody records per DSCSA.
FDA inspection readiness: NJ has a high density of FDA district inspectors and frequent pharmaceutical facility inspections. Your label validation records — including barcode verification results and serialization batch records — should be readily retrievable.
DSCSA compliance is non-negotiable, and label quality is where compliance succeeds or fails on the production floor. Certified Labeling Solutions has been producing pharmaceutical labels for NJ manufacturers since 1986, with direct experience in GS1 DataMatrix, NDC barcode printing, and variable-data serialization for the pharma supply chain.
Need DSCSA-compliant labels for your pharmaceutical products? Call (908) 495-6235 or request a quote.
Get a free quote from NJ's trusted custom label manufacturer. We'll respond within one business day.
Get a Free QuoteChoosing between pre-printed pressure-sensitive labels and on-demand thermal printing? This guide covers cost, performance, volume, and use cases for each approach.
Read Article →ANSI/ISO barcode grading tells you exactly how well your barcodes will scan. Here's what each grade means, what causes low grades, and when you need a grade report.
Read Article →